v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Revenue $ 64,179 $ 79,025
Operating expenses:    
Cost of revenue 38,335 33,676
Selling, general and administrative 40,885 38,671
Research and development 5,032 4,145
Restructuring (1,212) 0
Total operating expenses 83,040 76,492
(Loss) income from operations (18,861) 2,533
Other income (expense):    
Interest expense (10,864) (11,833)
Interest income 7,210 6,045
Change in payable to related parties pursuant to the Tax Receivable Agreement 0 (1,436)
Other income 106 168
Loss before income taxes (22,409) (4,523)
Income tax expense (benefit) 271 (3,175)
Net loss (22,680) (1,348)
Net loss attributable to non-controlling interests (10,602) (1,281)
Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (12,078) $ (67)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic (in usd per share) $ (0.09) $ (0.00)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., diluted (in usd per share) $ (0.09) $ (0.00)
Weighted average number of Class A common shares outstanding, basic (in shares) 132,333 131,739
Weighted average number of Class A common shares outstanding, diluted (in shares) 132,333 131,739

Source